Select Page

The latest report on “Erythropoietin Drugs Market (Drug Class – Biologics, and Biosimilars; Product – Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, and Other Products; Applications – Cancer, Hematology, Renal Diseases, and Neurology): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025.” The global erythropoietin drugs market is projected to grow at a CAGR of 10.2% over the forecast period of 2019-2025.

Ask for Sample Copy of Research Report with Table of Content @

Erythropoietin (EPO) was the first recombinant deoxyribonucleic acid (DNA) drug to arrive common medical use in the U.S. Medicare is by far the largest payer for EPO because Medicare covers about 93 percent of dialysis patients. As a result of Medicare coverage and payment regulations significantly influence the financial environment physicians and dialysis facilities face in attempting to balance the best care for patients with the fiscal reality. Hemoglobin levels and the dose of erythropoiesis-stimulating agents (ESAs) have increased in hemodialysis patients in the United States. It is a glycoprotein hormone that controls erythropoiesis or production of red blood cells. They are used in the treatment of different diseases like cancer and chronic renal diseases.

An increasing number of patients suffering from anemic condition induced due to cancer, HIV and End-Stage Renal Disease (ESRD) treatment is the major driving factor for the erythropoietin drugs market. Furthermore, factors such as the presence of large patient populations, patent expiration of biologics and an increase in the availability of biosimilars are other driving factors for the market growth. The use of EPO is held to increase oxygen absorption, reduce fatigue and improve endurance by increasing the rate of red cell production. It is also held that EPO increases the metabolism and the healing process of muscles because the extra red cells carry more oxygen and nutrients. Rising incidence of chronic kidney disease (CKD), cancer and HIV fueling the growth of the market. However, the high cost of EPO drugs is the major restraint factor for the erythropoietin drugs market. Moreover, patent expiration of major biologics during the coming years are anticipated to provide wide growth opportunities to the market players.

North America Dominates the Global Erythropoietin Drugs Market

Geographically, North America dominates the global erythropoietin drugs market owing to continuously increasing cancer population and patient suffering from renal diseases in this region. Europe is the second-largest market for erythropoietin drugs followed by Asia-Pacific.

Segment Covered

The report on global erythropoietin drugs market covers segments such as drug class, product, and applications. On the basis of drug class, the sub-markets include biologics, and biosimilars. On the basis of product, the sub-markets include epoetin-alfa, epoetin-beta, darbepoetin-alfa, and other products. On the basis of applications, the sub-markets include cancer, hematology, renal diseases, and neurology.

Browse Detailed TOC, Description, and Companies Mentioned in Report @

Companies Profiled:

The report provides profiles of the companies in the market such as Hospira Inc., Johnson & Johnson, Amgen Inc., Roche Holding AG, LG Life Sciences Ltd., Biocon Limited, Celltrion, Inc., Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and other companies.

Reasons to Buy this Report:

=> Comprehensive analysis of global as well as regional markets of the erythropoietin drugs.

=> Complete coverage of all the product type and application segments to analyze the trends, developments, and forecast of market size up to 2025.

=> Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.  

=> Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.